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The liver is one of the most common sites of metastasis and 
also gives rise to highly malignant primary cancers. 
Colorectal and pancreatic carcinomas are common sources 
of hepatic metastases, which are approximately 20 times 
more frequently found than the most common primary liver 
cancer, hepatocellular carcinoma (HCC) (Kadry et al. 
2001). Given the high prevalence and mortality rates of 
these focal lesions, a better molecular characterization is of 
great importance, especially because these lesions might 
also represent differential diagnostic problems.
Recently, proteins of the 26-member human claudin family 
were identified as participants in numerous normal and neo-
plastic processes (Mineta et al. 2011). Claudins are integral 
membrane proteins that form the indispensable backbone of 
tight junctions (TJs) (Tsukita and Furuse 1999). They play a 
crucial role in the cell-cell connection, maintaining epithelial 
cell polarity and regulating paracellular permeability (Martin 
and Jiang 2009). Besides these classical functions, claudins 
are newly discovered participants in various intriguing molec-
ular events—for example, claudin-1, -6, and -9 seem to act as 
co-receptors for hepatitis C virus entry (Meertens et al. 2008), 
whereas claudin-4 and -3 are target molecules of Clostridium 
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Summary
Tight junction proteins, including claudins, are often dysregulated during carcinogenesis and tumor progression. Moreover, 
the claudin expression pattern usually varies between different tumor entities. We aimed to investigate claudin expression 
profiles of primary and metastatic liver malignancies. We analyzed claudin-1, -2, -3, -4, and -7 expression by quantitative 
immunohistochemistry and real-time RT-PCR, respectively. Twenty hepatocellular carcinomas (HCCs) and liver metastases 
of 20 colorectal adenocarcinomas (CRLMs) and 15 pancreatic adenocarcinomas (PLMs) were studied together with 
paired surrounding non-tumorous liver samples and 5 normal liver samples. Strong claudin-3 and -7 immunohistochemical 
positivities were detected in CRLM samples, each with significantly stronger staining when compared with HCC and PLM 
groups. Claudin-1 protein was found highly expressed in CRLM, in contrast to lower expression in PLM and HCC. CRLMs 
and PLMs also were strongly positive for claudin-4, while being virtually undetectable in HCC. Claudin-2 showed strong 
positivity in non-tumorous liver tissue, whereas significantly weaker positivity was observed in all tumors. Differences in 
mRNA expression were mostly similar to those found by immunohistochemistry. In conclusion, HCC and both CRLM and 
PLM display distinct claudin expression profiles, which might provide better understanding of the pathobiology of these 
lesions and might be used for differential diagnosis. (J Histochem Cytochem 61:294–305, 2013)
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perfringens enterotoxin (Sonoda et al. 1999). Moreover, cer-
tain claudins have been implicated to be involved in carcino-
genesis and even in tumor progression and metastasis 
formation. For example, claudin-1 overexpression alone was 
sufficient to provide invasive features to human liver cells 
(Yoon et al. 2010), whereas in colorectal cancer, claudin-1 is 
a suggested target of the β-catenin/Tcf signaling cascade 
(Miwa et al. 2001). Low claudin-4 expression was clearly 
correlated with invasion and metastasis of pancreatic cancer 
cells (Michl et al. 2003), and claudin-7 downregulation has 
also been shown to increase cell growth and invasion in 
esophageal cancer (Lioni et al. 2007). Increased expression 
of claudin-10 in HCC was suggested to be associated with 
invasiveness, recurrence, and shorter survival (Ip et al. 2007; 
Huang et al. 2011).
It is also noteworthy that claudins are expressed in a 
tissue-specific manner. Moreover, unique claudin composi-
tion is also characteristic of cancerous tissues, which exhibit 
tumor type- and even differentiation-specific up- or down-
regulation of certain claudins (Soini 2005; Nemeth et al. 
2009; Szabo et al. 2009; Szekely et al. 2011; Torzsok et al. 
2011). These specific patterns can even be exploited as dif-
ferential diagnostic (Soini 2005; Lódi et al. 2006) or prog-
nostic tools (Szasz et al. 2011). It has also been shown that, 
in response to various stimuli, claudins can dynamically 
change (e.g., during the metastatic process), as cells must 
break down the adhesion barrier at the primary site and then 
reform junctions at the site of metastasis (Martin and Jiang 
2009). This might explain why claudin expression can dif-
fer between the primary and metastatic lesion of the same 
tumor (Tabaries et al. 2011). Moreover, tight junction pro-
teins are involved in signal transduction and regulatory 
pathways (Balda and Matter 2009); consequently, the loss 
of cell-cell contact does not necessarily mean general down-
regulation of all claudins: Certain claudins are downregu-
lated, whereas others are overexpressed.
Although it is clear that claudins might be key factors in 
tumor progression and many of them are suggested modula-
tors of invasion and metastasis, there is limited knowledge 
about the claudin phenotype of metastatic lesions, especially 
regarding human samples (Ueda et al. 2007; Merikallio et al. 
2011). Claudin expression alterations in primary cancers are 
much better characterized, including those of the breast 
(Kominsky et al. 2003; Tokes et al. 2005), colon (de Oliveira 
et al. 2005; Dhawan et al. 2005), prostate (Long et al. 2001), 
and pancreas (Nichols et al. 2004; Borka et al. 2007). Our 
group has also previously defined tight junctional protein 
changes in primary and metastatic cancers of the liver. For 
example, Lódi et al. (2006) found significantly increased 
claudin-4 expression in biliary tract cancers, which could 
differentiate tumors of biliary and hepatocellular origin, 
whereas the study by Orbán et al. (2008) revealed no occlu-
din and zonula occludens-1 expression in HCC and high 
expression in colorectal liver metastasis.
To our knowledge, no study is available regarding com-
parative characterization of claudin expression profiles in 
hepatocellular carcinoma and liver metastases of gastroin-
testinal tumors. Therefore, in the present study, we aimed to 
investigate claudin-1, -2, -3, -4, and -7 expression in the 
most common primary liver carcinoma—HCC—and the 
most common metastatic liver cancer—colorectal liver 
metastasis (CRLM). In addition, because of shared devel-
opmental roots and supposed shared features between bili-
ary tract cancers and pancreatic ductal adenocarcinoma 
(Geller et al. 2008), pancreatic liver metastasis (PLM) was 
also included in our study.
Materials and Methods
Tissue Samples
Surgically removed tissue specimens of 20 HCC, 20 
CRLM, and 15 PLM cases with corresponding surrounding 
non-tumorous liver tissues were enrolled in the present 
study with the permission of the Regional Ethical Committee 
of the Semmelweis University (#137/2008). Tissue samples 
were collected over an 8-year period and the diagnoses 
were reevaluated and confirmed by expert pathologists (ZS, 
AK, GL) and further supported by clinical data specific to 
the location of the primary tumor. The median age and 
female to male ratio in the patient groups were as follows: 
65 years, 7:13 (HCC); 65 years, 7:13 (CRLM); and 58 
years, 9:6 (PLM). Five normal liver (NL) samples were 
obtained from patients who died in accidents.
Histology and Immunohistochemistry
Tissue samples were fixed in 10% neutral-buffered forma-
lin and embedded in paraffin (FFPE), then cut and routinely 
stained with hematoxylin-eosin to establish the diagnosis.
Immunohistochemical detection of claudin-1, -2, -3, -4, 
and -7 proteins was performed on 3- to 4-µm-thick FFPE 
sections. Reactions were carried out using the Ventana ES 
automatic immunostainer (Ventana Medical Systems; 
Tucson, AZ) with the streptavidin-biotin-peroxidase tech-
nique and 3,3′-diaminobenzidine tetrahydrochloride as the 
chromogen. Well-characterized primary antibodies against 
claudin-1, -2, -3, -4, and -7 (Zymed; San Francisco, CA) 
were diluted 1:100 (Soini 2005; Laurila et al. 2007; Moldvay 
et al. 2007; Torzsok et al. 2011). Monoclonal mouse anti-
bodies against claudin-2 and -4 and polyclonal rabbit anti-
bodies against claudin-1, -3, and -7 were used. For negative 
controls, the specific antibody was omitted and either the 
antibody diluent alone or isotype-matched IgG serum 
was used. Positive controls were normal skin epithelium 
(claudin-1), normal colon mucosa (claudin-2, -3, -4), and 
breast ductal cells (claudin-7), as recommended by the 
manufacturer.
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Morphometrical Analysis
From each slide, 10 non-overlapping photographs 
were taken (×60 objective, Olympus BX50 micro-
scope; Olympus Corporation, Tokyo, Japan), and quan-
tification of the immunohistochemical staining was 
performed using Leica QWin V3 morphometrical soft-
ware (Leica Microsystems Imaging Solutions Ltd.; 
Cambridge, UK). Quantification was done by measur-
ing the area of immunohistochemical positivity, which 
correlates with both the presence and strength of the 
staining (Szekely et al. 2011). Area positivity above 3% 
was considered strong, 1.5% to 3% was moderate, and 
below 1.5% was weak.
Real-Time RT-PCR Analysis
RNA isolation. Histology-guided manual dissection of 
FFPE samples (20 HCC, 20 CRLM, 20 PLM, 5 NL) was 
performed, and tumorous and non-tumorous samples were 
processed separately. Total RNA was isolated with the High 
Pure RNA Paraffin Kit (Roche; Indianapolis, IN) according 
to the manufacturer’s instructions. Proteinase K digestion 
time was 16 h for each sample.
Reverse transcription. In total, 2 µg total RNA was reverse 
transcribed in a 20-µl mix of the High Capacity RNA-to-
cDNA Kit (Applied Biosystems [ABI]; Foster City, CA) 
according to the manufacturer’s protocol.
Real-time RT-PCR. Real-time PCR reactions for clau-
din-1, -2, -3, -4, and -7 and β-actin (reference gene) were 
carried out in duplicates, applying 100 ng cDNA template 
in a total volume of 25 µl SYBR Green PCR Master Mix 
(ABI; AB4309155). The primer sequences are listed in 
Table 1. Real-time PCR conditions were as follows: ini-
tial denaturation at 95C for 2 min, then 40 cycles at 95C 
for 20 sec, 60C for 30 sec, and 72C for 1 min, using the 
ABI Prism 7000 sequence detection system (ABI). Rela-
tive quantification of target gene expression was per-
formed using the E = 2ΔCq (ΔCq = Cq
reference
 – Cq
target
) 
method, with the average value of β-actin reactions as 
reference.
Statistical Analysis
Statistical analysis was carried out using STATISTICA 
software v8.0 (StatSoft; Tulsa, OK). The surrounding non-
tumorous livers were treated as one group for statistics. To 
examine the differences between the studied groups, the 
non-parametric Kruskal-Wallis test was used. Differences 
were considered statistically significant when p<0.05.
Results
Immunohistochemistry and Morphometry
Membranous claudin-1 positivity was predominantly 
detected in an apical localization in HCC cells organized in 
trabecular/glandular/acinar structures (Fig. 1a), whereas an 
almost completely circumscribed positivity was revealed in 
tumor cells of CRLM and PLM (Fig. 1b,c). Normal and 
non-tumorous tissue surrounding liver bile ducts showed 
intense positivity, whereas hepatocytes revealed faint posi-
tivity, mainly in the apical position (Fig. 1d). Morphometrical 
analysis showed that the mean area percentage of claudin-1 
staining was highest in the CRLM group (Table 2, Fig. 2a), 
although the difference between CRLM and the two other 
cancer groups became statistically significant only when 
the non-tumorous groups were excluded from the Kruskal-
Wallis statistical comparison (Fig. 2f; CRLM vs HCC, 
p=0.032; CRLM vs PLM, p=0.008).
Claudin-2 immunostaining resulted in granular cytoplas-
mic positivity in both tumorous (Fig. 1e–g) and normal 
cells (Fig. 1h). A significant decrease in the stained area 
percentage was observed in all three tumor groups when 
compared with the surrounding non-tumorous liver tissue 
(Fig. 2b), where both bile ducts and hepatocytes stained 
intensely.
Claudin-3 gave a significantly stronger membranous 
reaction in CRLM (Fig. 1j) than in the other groups (Fig. 
2c). HCC and non-tumorous liver cells exhibited weak and 
scattered positivity (Fig. 1i), along with stronger bile duct 
positivity (Fig. 1l). A weak and focal claudin-3 signal was 
also present in 10 of 15 PLM samples (Fig. 1k).
Table 1. Primer Sequences (5′–3′) and Amplicon Sizes of Claudins and β-actin
Gene Forward Reverse Amplicon Size, bp
claudin-1 GTG CGA TAT TTC TTC TTG CAG G TTC GTA CCT GGC ATT GAC TGG 113
claudin-2 CTC CCT GGC CTG CAT TAT CTC ACC TGC TAC CGC CAC TCT GT 91
claudin-3 CTG CTC TGC TGC TCG TGT CC TTA GAC GTA GTC CTT GCG GTC GTA G 129
claudin-4 GGC TGC TTT GCT GCA ACT GTC GAG CCG TGG CAC CTT ACA CG 108
claudin-7 CAT CGT GGC AGG TCT TGC C GAT GGC AGG GCC AAA CTC ATA C 118
β-actin CCT GGC ACC CAG CAC AAT GGG CCG GAC TCG TCA TAC 144
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Figure 1. Claudin expression in HCC (hepatocellular carcinoma), CRLM (colorectal liver metastasis), PLM (pancreatic liver metastasis), 
and NL (normal liver). (a, b, c, d) Claudin-1 in HCC, CRLM, PLM, and NL, respectively. (e, f, g, h) Claudin-2 in HCC, CRLM, PLM, and NL, 
respectively. (i, j, k, l) Claudin-3 in HCC, CRLM, PLM, and NL, respectively. (m, n, o, p) Claudin-4 in HCC, CRLM, PLM, and NL, respectively. 
(q, r, s, t) Claudin-7 in HCC, CRLM, PLM, and NL, respectively. Each photograph was taken with the same magnification. Scale bar: 50 µm
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Claudin-4 showed definite strong membrane positivity 
in all CRLM and PLM samples (Fig. 1n,o) with no signifi-
cant difference between these two groups (Fig. 2d). By con-
trast, this protein was virtually undetectable in HCC cells 
(Fig. 1m) and non-tumorous hepatocytes, but bile duct cells 
of non-tumorous and normal liver were positive (Fig. 1p).
Claudin-7 also showed significantly increased membra-
nous positivity in CRLM (Fig. 1r), in comparison with the 
other groups (Fig. 2e). Of 15 PLM cases, only 9 showed 
faint and focal positivity (Fig. 1s), and only weak staining 
was present on normal hepatocytes and hepatocellular car-
cinoma cells (Fig. 1q,t).
In summary, HCC is associated with moderate claudin-1, 
weak claudin-2, -3, and -7, and no claudin-4 positivity. 
CRLM is characterized by strong claudin-1, -3, -4, and -7 
and weak claudin-2 positivity, whereas strong claudin-4 and 
moderate or weak claudin-1, -2, -3, and -7 positivity are 
characteristic of PLM. Regarding the differentiation of 
HCC, claudin-1 positivity showed an increasing tendency 
to be expressed along with higher grades of HCC, which, 
however, did not prove to be significant. The other claudins 
did not reveal an association with grading (Suppl. Fig. 1.).
Real-Time RT-PCR Analysis
The differences in claudin expression at the protein level 
were mostly mimicked by differences in relative mRNA 
expression (β-actin was used as reference) (Table 3, Fig. 
3.). Claudin-3 and -4 mRNA levels were in great concor-
dance with morphometry, because their expression in 
CRLM were significantly higher than in non-tumorous sur-
rounding liver (SL) and HCC. A significant difference was 
also present between CRLM and PLM regarding claudin-3. 
Furthermore, claudin-7 mRNA in CRLM was found to be 
significantly higher than in PLM and SL, although levels in 
HCC were comparable to levels in CRLM. Also coincident 
Table 2. Results of Morphometry with Statistical Comparison of Individual Groups
Results of Morphometry  
 Group Area % SEM
K-W Test,  
p Value
vs CRLM,  
p Value
vs PLM,  
p Value
vs SL,  
p Value
vs NL,  
p Value
Claudin-1 HCC 1.83 0.41 <0.001* 0.443 1.000 0.390 1.000
 CRLM 5.29 0.88 0.115 <0.001* 0.140
 PLM 1.45 0.49 1.000 1.000
 SL 0.67 0.11 1.000
 NL 0.42 0.18  
Claudin-2 HCC 1.35 0.23 <0.001* 1.000 1.000 <0.001* 0.386
 CRLM 0.98 0.27 1.000 <0.001* 0.085
 PLM 1.82 0.39 0.001* 1.000
 SL 4.29 0.18 1.000
 NL 3.33 0.61  
Claudin-3 HCC 0.31 0.07 <0.001* <0.001* 1.000 1.000 1.000
 CRLM 7.61 1.09 <0.001* <0.001* 0.026*
 PLM 0.79 0.25 1.000 1.000
 SL 0.45 0.09 1.000
 NL 0.28 0.08  
Claudin-4 HCC 0.00 0.00 <0.001* <0.001* <0.001* 0.046* 0.635
 CRLM 10.82 0.63 1.000 <0.001* 0.029*
 PLM 7.16 0.98 <0.001* 0.212
 SL 0.01 0.00 1.000
 NL 0.01 0.00  
Claudin-7 HCC 0.38 0.09 <0.001* <0.001* 1.000 0.443 1.000
 CRLM 9.32 0.93 <0.001* <0.001* 0.001*
 PLM 0.57 0.20 1.000 1.000
 SL 0.22 0.05 1.000
 NL 0.10 0.06  
Mean and standard error values of morphometric analysis are listed. Statistical comparison of horizontal versus vertical groups was performed using 
the Kruskal-Wallis test. Significant differences (p<0.05) are marked by asterisks. CRLM, colorectal liver metastasis; HCC, hepatocellular carcinoma; K-W, 
Kruskal-Wallis; NL, normal liver; PLM, pancreatic liver metastasis; SEM, standard error of mean; SL, surrounding non-tumorous liver.
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with morphometrical results, claudin-2 levels in HCC and 
CRLM were lower than in SL, with the difference reaching 
statistical significance for HCC, although this downregula-
tion could not be observed in PLM. A striking difference 
was observed between protein and mRNA expression for 
claudin-1, which, instead of the expected upregulation, 
showed significant downregulation in CRLM when com-
pared with HCC and SL; PLM also showed lower mRNA 
levels than HCC and SL.
mRNA expression did not differ significantly with 
respect to the different grades of HCC (Suppl. Fig. 2.).
Discussion
Claudins are the main constituents of tight junctions, and sev-
eral lines of evidence propose that they contribute to the neo-
plastic processes. The altered expression of certain claudins 
can influence cancer progression indirectly by impairing tight 
junction functions or directly by modulating neoplastic signal-
ing pathways. Furthermore, unique claudin profiles of differ-
ent cancers are recognized to carry diagnostic, prognostic, and 
even therapeutic potential (Wang et al. 2011; Soini 2012).
Primary hepatocellular carcinoma and colorectal and 
pancreatic carcinomas are among the five most lethal carci-
nomas, and the latter two exhibit frequent association with 
liver metastases (Centeno 2006). Given that 90% of cancer-
related deaths are due to metastases (Christofori 2006), of 
which hepatic metastases represent a great percentage, 
identification of metastasis-related molecular patterns is 
just as important as that of primary cancers. Thus, molecu-
lar profiling is crucial for a better understanding of these 
liver lesions and may contribute to a better therapeutic 
approach to these tumors in the future. Moreover, these pro-
files carry great differential diagnostic value.
To our knowledge, this is the first report to address com-
parative claudin characterization of primary and metastatic 
Figure 2. Results of morphometric 
analysis. Stained area percentage of 
individual samples for each claudin 
(CLDN). Lines indicate the mean 
value of the groups. Asterisks mark 
significant differences (p<0.05). HCC 
(hepatocellular carcinoma), CRLM 
(colorectal liver metastasis), PLM 
(pancreatic liver metastasis), SL 
(surrounding non-tumorous liver), 
and NL (normal liver). Panel a shows 
the result of Kruskal-Wallis analysis, 
including non-tumorous groups, 
whereas panel f demonstrates the 
result of an analysis excluding non-
tumorous groups
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neoplasms of the liver. In the present study, distinct claudin 
expression profiles of HCC, CRLM, and PLM were identi-
fied: HCC moderately expressed claudin-1, weakly expressed 
claudin-2, -3, and -7, and lacked claudin-4. CRLM was char-
acterized by strong claudin-1, -3, -4, and -7 and moderate 
claudin-2 positivities, whereas PLM showed strong claudin-4, 
moderate claudin-2, and weak claudin-1, -3, and -7 stainings.
The role of certain claudins in tumorigenesis and tumor 
progression, particularly in metastasis formation, is largely 
undefined and sometimes appears contradictory. Whether 
overexpression of certain claudins is a cellular mechanism to 
compensate for the impaired tight junction function (Hadj-
Rabia et al. 2004; Cheung et al. 2012) or is deeply involved 
in neoplastic signaling pathways is not yet clearly under-
stood. However, tight junction strand disorganization and 
increased paracellular leakage were observed in colorectal 
tumor tissues despite upregulation of several claudins (de 
Oliveira et al. 2005), indicating that overexpression is not 
effective in maintaining tight junction function and thus may 
have other effects on cellular homeostasis.
Claudin-1 is one of the best characterized molecules of 
the claudin protein family, and its direct involvement in 
tumor progression and metastasis seems to be unequivocal, 
although there are some discrepancies as to its exact role in 
these processes. In colorectal carcinoma, overexpression 
and knockdown experiments support a role for claudin-1 as 
a promoter of invasion and metastasis, and a positive cor-
relation between claudin-1 expression and tumor progres-
sion and metastasis has been established (Dhawan et al. 
2005). In line with this, frequent upregulation of claudin-1 
in human colorectal cancer tissues has been observed in 
several studies (de Oliveira et al. 2005; Grone et al. 2007; 
Kinugasa et al. 2007; Oshima et al. 2008; Huo et al. 2009). 
On the other hand, low claudin-1 expression seemed to cor-
relate with poor differentiation, poor prognosis (Resnick 
et al. 2005), and lymph node metastasis in colorectal cancer 
(Ersoz et al. 2011), whereas, in lung adenocarcinoma, clau-
din-1 overexpression has been shown to suppress cancer 
invasion and metastasis (Chao et al. 2009). Interestingly, 
similarly controversial results can be found regarding HCC, 
Table 3. Results of Real-time RT-PCR Analysis with Statistical Comparison of Individual Groups
Results of Real-Time RT-PCR  
 Group 2ΔCq(actin – cldn) SEM
K-W Test,  
p Value
vs CRLM,  
p Value
vs PLM,  
p Value
vs SL,  
p Value
vs NL,  
p Value
Claudin-1 HCC 0.35 0.07 <0.001* 0.012* 0.537 1.000 1.000
 CRLM 0.11 0.03 1.000 <0.001* 0.004*
 PLM 0.15 0.02 0.006* 0.062
 SL 0.49 0.05 1.000
 NL 0.86 0.25  
Claudin-2 HCC 0.02 0.01 <0.001* 0.927 <0.001* <0.001* 0.461
 CRLM 0.03 0.01 0.001* 0.208 1.000
 PLM 0.15 0.03 0.128 0.791
 SL 0.09 0.02 1.000
 NL 0.09 0.05  
Claudin-3 HCC 0.05 0.01 <0.001* <0.001* 1.000 1.000 1.000
 CRLM 0.27 0.05 0.001* <0.001* 1.000
 PLM 0.05 0.02 1.000 1.000
 SL 0.07 0.02 1.000
 NL 0.09 0.02  
Claudin-4 HCC 0.01 0.00 <0.001* <0.001* 0.003* 1.000 1.000
 CRLM 0.08 0.02 1.000 <0.001* 0.229
 PLM 0.03 0.01 0.024* 1.000
 SL 0.01 0.00 1.000
 NL 0.02 0.01  
Claudin-7 HCC 0.02 0.00 <0.001* 0.111 0.011* 1.000 1.000
 CRLM 0.03 0.01 <0.001* <0.001* 0.679
 PLM 0.00 0.00 0.051* 0.454
 SL 0.01 0.00 1.000
 NL 0.01 0.01  
Mean and standard error values of real-time RT-PCR analysis are listed. Statistical comparison of horizontal versus vertical groups was performed using 
the Kruskal-Wallis test. Significant differences (p<0.05) are marked by asterisks. CRLM, colorectal liver metastasis; HCC, hepatocellular carcinoma; K-W, 
Kruskal-Wallis; NL, normal liver; PLM, pancreatic liver metastasis; SEM, standard error of mean; SL, surrounding non-tumorous liver.
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in which reduced claudin-1 expression was shown to closely 
correlate with tumor dedifferentiation and poor prognosis 
(Higashi et al. 2007). Yet, HCC cell line experiments sup-
ported a role for claudin-1 as a potent inducer of cancer cell 
invasion (Yoon et al. 2010). In the present study, definite 
claudin-1 positivity was found in both primary HCC and 
metastatic colorectal and pancreatic carcinomas, underlin-
ing the involvement of this protein in hepatocarcinogenesis 
and metastasis formation. Our data on the increasing expres-
sion of claudin-1 with higher grades of HCC are also sup-
ported by a recent publication by Suh et al. (2012), which 
suggests a role for claudin-1 in epithelial-mesenchymal 
transition in hepatocarcinogenesis.
It has been shown that claudin-2 expression diminishes 
during breast cancer progression at the primary site (Kim et al. 
2008), but the expression is regained in liver-metastasizing 
breast cancer cells, thus playing a promoter role in the for-
mation of liver metastases (Tabaries et al. 2011). In our 
sample set, we found weak or moderate claudin-2 positivity 
in liver metastases of colorectal and pancreatic cancers. 
Obvious claudin-2 expression has already been described in 
25.3% of colorectal (Aung et al. 2006) and 45% of pancre-
atic adenocarcinomas (Borka et al. 2007). Thus, claudin-2 
may not only participate in the carcinogenesis of these 
tumors but may also contribute to a metastatic phenotype. 
Interestingly, we found a significant downregulation of 
claudin-2 at both protein and mRNA levels in HCC when 
compared with normal and surrounding liver tissues. 
Intriguingly, claudin-2 was shown to be positively regulated 
by the hepatocyte nuclear factor–1α (HNF-1α) (Sakaguchi 
et al. 2002), a factor with reduced expression in HCC (Zeng 
et al. 2011), and was also shown to be required for proper 
hepatic polarization (Son et al. 2009), which is frequently 
lost in tumors. Taken together, these results seem to support 
a tumor-suppressive role for claudin-2 in hepatocellular 
carcinogenesis.
Since the discovery of claudin-3 and -4 as receptors for 
the cytotoxic C. perfringens enterotoxin (Sonoda et al. 
1999), much attention has been given to these claudin iso-
forms. Claudin-4, for example, soon became a candidate for 
claudin-based antitumor therapies (Suzuki et al. 2009) and 
the target of novel therapeutic approaches (Neesse et al. 
2012). Claudin-4 expression was proposed to be a typical 
feature of adenocarcinomas (Michl et al. 2003), and frequent 
upregulation was described in several tumors, among others 
in colorectal carcinoma (Oshima et al. 2008), ovarian carci-
noma (Rangel et al. 2003), biliary tract cancer (Nemeth et al. 
2009), and pancreatic carcinoma (Borka et al. 2007). On the 
other hand, impaired claudin-4 expression seemed to be 
associated with less differentiated and invasive phenotypes, 
suggesting its inhibitory effect on invasion and metastasis of 
both pancreatic (Michl et al. 2003) and colorectal carcino-
mas (Ueda et al. 2007). Interestingly, when metastases of 
these tumors were investigated, decreased expression was 
documented in colorectal liver metastases (Ueda et al. 2007; 
Georges et al. 2012), but maintained claudin-4 positivity 
was reported in pancreatic liver metastases (Nichols et al. 
2004). In our present study, both PLM and CRLM strongly 
expressed claudin-4, which underlines its role in the patho-
genesis of these lesions. Considering HCC, no claudin-4 
positivity was detected, which is in line with our previous 
findings (Lódi et al. 2006).
In our sample set, a faint claudin-3 signal was found 
in HCCs along with strong claudin-3 positivity in CRLM 
Figure 3. Differences in claudin (CLDN) mRNA expression relative to β-actin. Asterisks mark significant differences (p<0.05). ( ) 
HCC (hepatocellular carcinoma), ( ) CRLM (colorectal liver metastasis), ( ) PLM (pancreatic liver metastasis), ( ) SL (surrounding non-
tumorous liver), ( ) NL (normal liver)
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samples, and high levels already have been described in pri-
mary colorectal carcinoma (Oshima et al. 2008; Chen et al. 
2010). An interesting finding of the present study was the 
presence of claudin-3 positivity in PLM samples. This can 
be important because no claudin-3 staining was detected in 
primary pancreatic cancer (Borka et al. 2007). Furthermore, 
intrahepatic bile duct cancers (IBDCs) were also character-
ized by the scarcity or absence of this claudin (Nemeth 
et al. 2009). Thus, claudin-3 expression might contribute to 
the metastatic progression of pancreatic carcinoma and 
could also be used to differentiate between IBDC and PLM.
Tumorigenic roles of claudin-7 in colorectal carcinoma 
cell lines have previously been described (Darido et al. 
2008), and claudin-7 was proposed to exert its roles in com-
plex with other proteins (Kuhn et al. 2007). Moreover, the 
frequent expression of claudin-7 and its associated mole-
cules were detected in both primary colorectal carcinoma 
samples and liver metastases. In concordance with these 
results, we also found strong claudin-7 positivity in CRLM 
samples, but reduced claudin-7 expression was described to 
correlate with metastasis formation in esophageal (Usami et al. 
2006) and breast (Sauer et al. 2005) cancers. Interestingly, 
early reduction of claudin-7 mRNA levels was also described 
during colorectal carcinogenesis (Bornholdt et al. 2011), 
whereas reexpression of this molecule was frequently found 
in lymph node metastases (Nakayama et al. 2008); this 
might also explain its positivity in our liver metastases sam-
ples. Furthermore, HCC showed weak claudin-7 positivity, 
with no significant change in comparison to non-tumorous 
liver. This might be in parallel with the results of a trans-
genic mouse HCC model, in which only small tumors 
showed enhanced claudin-7 expression (Borlak et al. 2005). 
When comparing our findings on PLM with the results 
described in primary pancreatic carcinoma and IBDC, inter-
esting differences were observable. Claudin-7 positivity was 
described in all primary pancreatic adenocarcinomas (Borka 
et al. 2007) whereas, in PLMs, 6 cases were negative, and 
only 9 of 15 cases were faintly positive. In this regard, PLM 
appears to be more similar to bile duct cancers, which also 
exhibit low claudin-7 expression (Nemeth et al. 2009).
The above-described findings rather suggest a complex 
and well-regulated system of claudin expression that is dis-
tinct in primary and metastatic liver tumors. Downregulation 
of certain claudins has been shown in advanced stages of 
colorectal carcinomas, but we found strong claudin positivity 
in CRLM. Several factors may attribute to this change (e.g., 
biological selection of tumor cells in tumor progression and 
microenvironmental influence) (Georges et al. 2012). It has 
also been shown that dedifferentiated colorectal adenocarci-
nomas undergo redifferentiation in liver metastases (Kaihara 
et al. 2003), which might also mean recovery of the claudin 
phenotype at the more differentiated stages. In the present 
study, a good correlation between protein and mRNA expres-
sion was found, with two interesting exceptions regarding 
HCC. HCC showed lower claudin-1 and -7 protein positivity 
than did CRLM, whereas mRNA levels were higher or com-
parable. This raises the possibility of a posttranscriptional 
regulation of claudin expression that might be mediated by 
microRNAs (Kwak et al. 2010). Rapid protein turnover 
might also be responsible for the discrepancy.
Taken together, our findings support the role of altered 
claudin expression in both hepatocarcinogenesis and metas-
tasis formation of colorectal and pancreatic cancers. We 
found that HCC, CRLM, and PLM differentially express 
claudin-1, -2, -3, -4, and -7, which might even be exploited in the 
differential diagnosis of these tumor entities. Strong positivity 
of claudin-1, -3, -4, and -7 is characteristic of CRLM; HCC is 
associated with claudin-1 staining and a lack of claudin-4; 
and PLM shows strong claudin-4 and weak claudin-1 posi-
tivity. Furthermore, possible claudin-targeting or claudin-
anchored therapies could be aimed at not only treating 
primary liver tumors, but patients with metastatic liver dis-
ease could also benefit from such therapeutic approaches. In 
conclusion, primary hepatocellular carcinoma and metastatic 
colorectal and pancreatic carcinomas display distinct claudin 
expression profiles. This provides further understanding of 
their pathobiology and might aid in the differential diagnosis 
of focal liver lesions. The observed expression changes 
clearly implicate these claudins in the process of carcinogen-
esis and metastasis formation.
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